Successful Stakeholder Meeting boosts energy for future collaborative drug discovery

“It started as an experiment…”

Speakers highlight ELF as key player in collaborative drug discovery

The ELF Stakeholder Meeting brought together more than 90 participants from 60 different organisations, based in 14 different countries, reflecting the European aspect of ELF. The participants represent a broad group of involved stakeholders, ranging from policy and science to business and healthcare. An enthusiastic audience joined for more than ten presentations, discussions and multiple opportunities to network with programme owners and other experts.

Dimitrios Tzalis (ELF Head of Chemistry) and Ton Rijnders (ELF Head of Screening) kicked off the Stakeholder Meeting. They introduced the European Lead Factory as a real pioneer in collaborative drug discovery. When ELF started recruiting the initial screening programmes, the concept was new to the community and questions were raised whether it could deliver on its promises. Dimitrios and Ton showed how ELF has now become a powerful drug discovery engine, by visualising the astonishing results and impact achieved in the past five years. Ton Rijnders: “It started as an experiment, that would be characterized by shared use of compound collections, crowdsourcing innovations, creating partnerships and generating value. Now I dare to say, when looking at these four items: we can successfully tick off all those boxes.”

Dimitrios Tzalis said: “Globally there are many unmet medical needs that have to be addressed for patients in need. The primary goal of ELF is to deliver hit compounds that in turn can be translated into patents and drug candidates with the ultimate goal in mind to improve patients’ lives. ELF is a very good instrument to address this challenge, due to the fact that it provides the early drug discovery community with the resources required to identify and move potential drug candidates faster to the clinic”.

Read the full press success story here

About Taros Chemicals

Taros is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Taros’ drug discovery mission is to create drug candidates as potential new medicines. Taros has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Taros’ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.
Taros was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, Taros is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.

Press Contact:
Youri R. Mesmoudi, Executive Vice President, e-mail: innovation |at|

medicinal chemistry

drug discovery

We are running our own state-of-the-art Drug Discovery Chemistry facilities in Germany with the option for process research chemistry, upscaling, kilolab production…

performance chemicals

material science

We create performance chemicals to enhance new materials, plastics, coatings, dyes & inks, cosmetics, flavors and many more research and industrial applications…


Looks interesting?

As a leading contract research organization in discovery chemistry and custom synthesis, Taros provides comprehensive solutions to meet our clients’ needs from diverse branches and applications

Our experienced chemists practice a pragmatic culture and customer-centric approach in order to exceed project expectations, despite challenges, bridging very narrow timelines. They are trained to consider economic, safety and ecological boundaries and conditions laid out for all stages of the project, starting from the development of synthetic routes to…

Drug Discovery Hub Dortmund